ADC Therapeutics SA
Company Profile
Business description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Contact
Route de la Corniche 3B
Biopole
Epalinges1066
CHET: +41 216530200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
263
Stocks News & Analysis
stocks
Will China strong arm BHP into lower iron ore prices?
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,277.90 | 18.60 | -0.20% |
| CAC 40 | 8,060.13 | 85.28 | 1.07% |
| DAX 40 | 24,597.13 | 211.35 | 0.87% |
| Dow JONES (US) | 46,601.78 | 1.20 | -0.00% |
| FTSE 100 | 9,548.87 | 65.29 | 0.69% |
| HKSE | 26,829.46 | 128.31 | -0.48% |
| NASDAQ | 23,043.38 | 255.02 | 1.12% |
| Nikkei 225 | 48,062.49 | 327.50 | 0.69% |
| NZX 50 Index | 13,582.81 | 14.33 | 0.11% |
| S&P 500 | 6,753.72 | 39.13 | 0.58% |
| S&P/ASX 200 | 8,973.70 | 21.30 | -0.24% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |